{
  "identity": {
    "bacteriumName": "Proteus sp.",
    "aliases": [
      "Proteus mirabilis",
      "Proteus penneri",
      "Proteus vulgaris"
    ],
    "lastUpdated": "2025-01-08",
    "clsiCategory": "Enterobacterales (excluding Salmonella/Shigella)",
    "classification": {
      "gramStain": "Gram negative",
      "morphology": "bacilli",
      "respiration": "Facultative anaerobe",
      "notes": [
        "motile (swarming on culture plate)"
      ]
    },
    "strainDetails": [
      {
        "type": "Complex Member",
        "value": "Proteus mirabilis",
        "notes": "indole negative"
      },
      {
        "type": "Complex Member",
        "value": "Proteus penneri",
        "notes": "indole negative"
      },
      {
        "type": "Complex Member",
        "value": "Proteus vulgaris",
        "notes": "indole positive"
      }
    ],
    "biochemicalTests": "Gram-negative rod, highly motile (swarming), lactose –, urease strongly +, phenylalanine deaminase +, H2S + (P. mirabilis, P. vulgaris)."
  },
  "clinicalProfile": {
    "summary": "Proteus sp. cause a variety of infections from uncomplicated UTIs to life-threatening infections of the abdomen, skin, soft tissue, and lungs in both normal and immunocompromised hosts. UTIs are the most common and are often catheter-associated.",
    "pathophysiologyPearls": [
      "Known for biofilm formation and producing a potent urease enzyme, which leads to alkaline urine and the formation of struvite stones (magnesium ammonium phosphate)."
    ],
    "keySignsAndSymptoms": [],
    "clinicalSyndromes": [
      {
        "syndromeName": "Urinary Tract Infections (UTI)",
        "description": "Most common infection type, frequently catheter-associated and can be complicated by the formation of struvite stones due to urease production."
      },
      {
        "syndromeName": "Intra-abdominal Infections",
        "description": "Can cause life-threatening infections of the abdomen."
      },
      {
        "syndromeName": "Skin and Soft Tissue Infections",
        "description": "Can cause life-threatening infections of the skin and soft tissue."
      },
      {
        "syndromeName": "Pneumonia",
        "description": "Can cause life-threatening infections of the lungs."
      }
    ],
    "stagesOfIllness": [],
    "highRiskPopulations": [
      "Immunocompromised hosts",
      "Patients with urinary catheters"
    ],
    "transmissionVectors": [],
    "prognosisNotes": [
      "Diagnostic imaging is recommended for upper tract or recurrent infections to assess for stones or obstructive uropathy."
    ]
  },
  "resistanceProfile": {
    "groupIntrinsicResistance": [],
    "intrinsicResistance": [
      {
        "drugOrClass": "Polymyxins",
        "notes": "Proteus species are intrinsically resistant to polymyxins (Colistin, Polymyxin B)."
      },
      {
        "drugOrClass": "Nitrofurantoin",
        "notes": "Proteus spp. are intrinsically resistant to Nitrofurantoin."
      }
    ],
    "majorMechanisms": [
      {
        "mechanismName": "ESBL (Extended-Spectrum Beta-Lactamase)",
        "mechanismType": "Enzymatic",
        "description": "Confers resistance to most penicillins and cephalosporins. Indole positive species (P. vulgaris) may overproduce ESBLs."
      },
      {
        "mechanismName": "AmpC Beta-Lactamase",
        "mechanismType": "Enzymatic",
        "description": "Resistance to aztreonam, ceftriaxone, and/or cefotaxime may indicate overproduction of AmpC."
      },
      {
        "mechanismName": "KPC (Klebsiella pneumoniae carbapenemase)",
        "mechanismType": "Enzymatic",
        "description": "A serine-based carbapenemase conferring resistance to all carbapenems. Can be overcome by new beta-lactamase inhibitor combinations like meropenem-vaborbactam or ceftazidime-avibactam."
      },
      {
        "mechanismName": "MBL (Metallo-Beta-Lactamase)",
        "mechanismType": "Enzymatic",
        "description": "Confers resistance to all carbapenems and newer beta-lactamase inhibitors (vaborbactam, avibactam). Requires alternative strategies like ceftazidime-avibactam + aztreonam or cefiderocol."
      }
    ],
    "clinicalAlerts": [
      {
        "alertTitle": "ESBL Production and Piperacillin-Tazobactam",
        "details": "Do not use piperacillin-tazobactam for suspected or proven ESBL production, as it may fail clinically despite in vitro susceptibility."
      },
      {
        "alertTitle": "Carbapenem Activity Variability",
        "details": "Imipenem is noted to be less active against Proteus spp. compared to other carbapenems. Check susceptibility of all carbapenems if considering their use."
      }
    ]
  },
  "treatment": {
    "generalNotes": [
      "The recommendations in the table are for moderately severe or severe infections.",
      "For less severe infections, options include Amoxicillin-clavulanate, fluoroquinolones, and second/third-gen cephalosporins.",
      "Amoxicillin may be active against P. mirabilis but not P. vulgaris.",
      "TMP-SMX can be used if susceptible.",
      "Proteus spp. are intrinsically resistant to Nitrofurantoin.",
      "Imipenem is less active than other carbapenems.",
      "Fosfomycin susceptibility is variable and should only be used for uncomplicated UTI if susceptible."
    ],
    "drugsToAvoid": [
      {
        "drugOrClass": "Nitrofurantoin",
        "condition": "All infections",
        "reason": "Intrinsic resistance."
      },
      {
        "drugOrClass": "Polymyxins (Colistin, Polymyxin B)",
        "condition": "All infections",
        "reason": "Intrinsic resistance."
      },
      {
        "drugOrClass": "Piperacillin-tazobactam",
        "condition": "Suspected or proven ESBL-producing infections",
        "reason": "Reported clinical failures despite in vitro susceptibility."
      },
      {
        "drugOrClass": "Imipenem-relebactam",
        "condition": "All infections",
        "reason": "CLSI breakpoints do not apply to the family Morganellaceae, which includes Proteus."
      }
    ],
    "adjunctiveTherapies": [],
    "regimens": [
      {
        "context": {
          "type": "Empiric",
          "condition": "Moderately severe or severe infection",
          "patientPopulation": [
            "Areas with local ESBL rate <15%"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "pending susceptibilities",
                "drugs": [
                  {
                    "drugName": "Piperacillin-tazobactam",
                    "dose": "4.5 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Administer over 4 hours."
                  }
                ]
              }
            ]
          },
          {
            "preference": "Alternative",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "pending susceptibilities",
                "drugs": [
                  {
                    "drugName": "Ciprofloxacin",
                    "dose": "400 mg",
                    "route": "IV",
                    "frequency": "bid",
                    "comments": ""
                  }
                ]
              }
            ]
          },
          {
            "preference": "Alternative",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "pending susceptibilities",
                "drugs": [
                  {
                    "drugName": "Levofloxacin",
                    "dose": "750 mg",
                    "route": "IV",
                    "frequency": "q24h",
                    "comments": ""
                  }
                ]
              }
            ]
          },
          {
            "preference": "Alternative",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "pending susceptibilities",
                "drugs": [
                  {
                    "drugName": "Cefazolin",
                    "dose": "1 gm",
                    "route": "IV",
                    "frequency": "q12h",
                    "comments": ""
                  }
                ]
              }
            ]
          },
          {
            "preference": "Alternative",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "pending susceptibilities",
                "drugs": [
                  {
                    "drugName": "Ceftriaxone",
                    "dose": "1-2 gm",
                    "route": "IV",
                    "frequency": "q24h",
                    "comments": ""
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Empiric",
          "condition": "Moderately severe or severe infection",
          "patientPopulation": [
            "Areas with local ESBL rate >15%"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "pending susceptibilities",
                "drugs": [
                  {
                    "drugName": "Meropenem",
                    "dose": "1-2 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "See alternative regimens for other options."
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "Indole positive Proteus (e.g., vulgaris) with resistance to aztreonam, ceftriaxone, and/or cefotaxime",
          "patientPopulation": [
            "Patients with isolates consistent with overproduction of ESBL and/or AmpC"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Course of therapy",
                "drugs": [
                  {
                    "drugName": "Meropenem",
                    "dose": "1-2 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Higher percentage of in vitro resistance to Imipenem compared to other carbapenems. Avoid Pip/tazo if ESBL production is suspected."
                  }
                ]
              }
            ]
          },
          {
            "preference": "Alternative",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Course of therapy",
                "drugs": [
                  {
                    "drugName": "Ertapenem",
                    "dose": "1 gm",
                    "route": "IV",
                    "frequency": "q24hr",
                    "comments": "See other alternatives if needed."
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "Carbapenem resistance, KPC suspected",
          "patientPopulation": [
            "Isolates resistant to all carbapenems but susceptible to meropenem-vaborbactam and ceftazidime-avibactam"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Course of therapy",
                "drugs": [
                  {
                    "drugName": "Meropenem-vaborbactam",
                    "dose": "4 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Administer over 3 hours. Infectious Diseases consultation recommended."
                  }
                ]
              }
            ]
          },
          {
            "preference": "Alternative",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Course of therapy",
                "drugs": [
                  {
                    "drugName": "Ceftazidime-avibactam",
                    "dose": "2.5 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Administer over 2 hours. Infectious Diseases consultation recommended."
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "Carbapenem resistance, Metallo-beta-lactamase (MBL) suspected",
          "patientPopulation": [
            "Isolates resistant to all carbapenems, meropenem-vaborbactam, and ceftazidime-avibactam"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Course of therapy",
                "drugs": [
                  {
                    "drugName": "Ceftazidime-avibactam",
                    "dose": "2.5 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Administer over 3 hours."
                  },
                  {
                    "drugName": "Aztreonam",
                    "dose": "2 gm",
                    "route": "IV",
                    "frequency": "q6h",
                    "comments": "Administer over 3 hours. Infectious Diseases consultation strongly recommended."
                  }
                ]
              }
            ]
          },
          {
            "preference": "Alternative",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Course of therapy",
                "drugs": [
                  {
                    "drugName": "Cefiderocol",
                    "dose": "2 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "Administer over 3 hours. Infectious Diseases consultation strongly recommended."
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "Less severe infection, no evidence of ESBL or plasmid-based AmpC production",
          "patientPopulation": [],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Alternative",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Course of therapy",
                "drugs": [
                  { "drugName": "Cefixime", "dose": "Varies", "route": "PO", "frequency": "Varies", "comments": "" },
                  { "drugName": "Cefpodoxime", "dose": "Varies", "route": "PO", "frequency": "Varies", "comments": "" },
                  { "drugName": "Cefdinir", "dose": "Varies", "route": "PO", "frequency": "Varies", "comments": "" }
                ]
              }
            ]
          },
          {
            "preference": "Alternative",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "1 dose",
                "drugs": [
                  {
                    "drugName": "Fosfomycin",
                    "dose": "3 gm",
                    "route": "PO",
                    "frequency": "x1",
                    "comments": "For UTI only. Use is discouraged for Proteus sp. as breakpoints are only for E.coli."
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "Any infection",
          "patientPopulation": [
            "Patients with a severe beta-lactam allergy"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Course of therapy",
                "drugs": [
                  {
                    "drugName": "Aztreonam",
                    "dose": "Varies",
                    "route": "IV",
                    "frequency": "Varies",
                    "comments": ""
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "ESBL-producing infection",
          "patientPopulation": [
            "Patient cannot receive a carbapenem"
          ],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Alternative",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Course of therapy",
                "drugs": [
                  { "drugName": "Aminoglycoside", "dose": "Varies", "route": "IV", "frequency": "Varies", "comments": "If susceptible." },
                  { "drugName": "Fluoroquinolone", "dose": "Varies", "route": "IV/PO", "frequency": "Varies", "comments": "If susceptible." },
                  { "drugName": "Ceftolozane-tazobactam", "dose": "1.5 gm", "route": "IV", "frequency": "q8h", "comments": "Administer over 3 hours." },
                  { "drugName": "Ceftazidime-avibactam", "dose": "2.5 gm", "route": "IV", "frequency": "q8h", "comments": "Administer over 3 hours." },
                  { "drugName": "Cefepime-enmetazobactam", "dose": "Varies", "route": "IV", "frequency": "Varies", "comments": "" },
                  { "drugName": "Temocillin", "dose": "2 gm", "route": "IV", "frequency": "q12h", "comments": "Where available." }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "Pan-resistant infection",
          "patientPopulation": [],
          "isolateSource": null
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Course of therapy",
                "drugs": [
                  {
                    "drugName": "Plazomicin",
                    "dose": "15 mg/kg",
                    "route": "IV",
                    "frequency": "once daily",
                    "comments": "If available. Infectious Diseases consultation needed."
                  }
                ]
              }
            ]
          }
        ]
      }
    ]
  },
  "laboratoryProfile": {
    "testingIndications": [
      "Cultures obtained from suspected sites of infection, such as urine, blood, wounds, or respiratory specimens."
    ],
    "methodologyNotes": [
      "Proteus species are known for their characteristic 'swarming' motility on non-inhibitory agar plates, which can sometimes complicate the isolation of other organisms in a mixed culture."
    ],
    "recommendedPanel": [],
    "specialTests": [
      {
        "testName": "Indole Test",
        "trigger": "Isolation of Proteus sp.",
        "purpose": "To differentiate between Proteus species. P. vulgaris is indole positive, while P. mirabilis and P. penneri are indole negative. This can have treatment implications as P. vulgaris may have different resistance patterns."
      }
    ],
    "reportingRules": [
      {
        "ruleType": "Surrogate",
        "drug": "Ampicillin",
        "condition": "All isolates",
        "details": "Results of ampicillin testing can be used to predict results for amoxicillin."
      },
      {
        "ruleType": "Surrogate",
        "drug": "Cefazolin",
        "condition": "Uncomplicated UTI caused by P. mirabilis",
        "details": "Cefazolin can be used as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."
      },
      {
        "ruleType": "Surrogate",
        "drug": "Tetracycline",
        "condition": "All isolates",
        "details": "Organisms susceptible to tetracycline are also considered susceptible to doxycycline and minocycline."
      },

      {
        "ruleType": "Conditional",
        "drug": "Cefepime",
        "condition": "Isolate demonstrates carbapenemase production.",
        "details": "Cefepime S/SDD results should be suppressed or reported as resistant."
      },
      {
        "ruleType": "Conditional",
        "drug": "Meropenem-vaborbactam",
        "condition": "An OXA-48-like gene or enzyme is detected.",
        "details": "Results should be suppressed or reported as resistant."
      },
      {
        "ruleType": "Exclusion",
        "drug": "Fosfomycin",
        "condition": "Any Proteus sp. isolate",
        "details": "Disk diffusion and MIC breakpoints for Fosfomycin apply only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species, including Proteus sp."
      },
      {
        "ruleType": "Exclusion",
        "drug": "Imipenem-relebactam",
        "condition": "Any Proteus sp. isolate",
        "details": "Breakpoints for imipenem-relebactam are explicitly stated not to apply to the family Morganellaceae, which includes Proteus."
      },
      {
        "ruleType": "General",
        "drug": "All",
        "condition": "All isolates",
        "details": "Laboratories generally follow cascade reporting rules, meaning that results for broader-spectrum agents (Tier 2 or 3) are often only reported if the isolate is resistant to primary, narrower-spectrum agents (Tier 1)."
      }
    ],
    "antimicrobialBreakpoints": [
      {
        "tier": 1,
        "tierDescription": "Appropriate for routine, primary testing and reporting.",
        "agents": [
          {
            "agentName": "Ampicillin",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "10 µg", "s_breakpoint": "≥ 17 mm", "i_breakpoint": "14–16 mm", "r_breakpoint": "≤ 13 mm" },
                "mic": { "s_breakpoint": "≤ 8 µg/mL", "i_breakpoint": "16 µg/mL", "r_breakpoint": "≥ 32 µg/mL" },
                "comments": [ "Results of ampicillin testing can predict results for amoxicillin." ]
              }
            ]
          },
          {
            "agentName": "Amoxicillin-clavulanate",
            "breakpointSets": [
              {
                "condition": "Uncomplicated UTI only",
                "diskDiffusion": { "diskContent": "20/10 µg", "s_breakpoint": "≥ 18 mm", "i_breakpoint": null, "r_breakpoint": "≤ 17 mm" },
                "mic": { "s_breakpoint": "≤ 8/4 µg/mL", "i_breakpoint": "16/4 µg/mL", "r_breakpoint": "≥ 32/4 µg/mL" },
                "comments": [ "Breakpoints when oral amoxicillin-clavulanate is used are only for therapy of uncomplicated UTIs due to E. coli and Proteus mirabilis." ]
              }
            ]
          },
          {
            "agentName": "Ampicillin-sulbactam",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "10/10 µg", "s_breakpoint": "≥ 15 mm", "i_breakpoint": "12–14 mm", "r_breakpoint": "≤ 11 mm" },
                "mic": { "s_breakpoint": "≤ 8/4 µg/mL", "i_breakpoint": "16/4 µg/mL", "r_breakpoint": "≥ 32/16 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Piperacillin-tazobactam",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "100/10 µg", "s_breakpoint": "≥ 25 mm", "i_breakpoint": "21–24 mm", "r_breakpoint": "≤ 20 mm" },
                "mic": { "s_breakpoint": "≤ 8/4 µg/mL", "i_breakpoint": "16/4 µg/mL", "r_breakpoint": "≥ 32/4 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Gentamicin",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "10 µg", "s_breakpoint": "≥ 18 mm", "i_breakpoint": "15–17 mm", "r_breakpoint": "≤ 14 mm" },
                "mic": { "s_breakpoint": "≤ 4 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 8 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Tobramycin",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "10 µg", "s_breakpoint": "≥ 17 mm", "i_breakpoint": "13–16 mm", "r_breakpoint": "≤ 12 mm" },
                "mic": { "s_breakpoint": "≤ 4 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 8 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Amikacin",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "30 µg", "s_breakpoint": "≥ 19 mm", "i_breakpoint": "17–19 mm", "r_breakpoint": "≤ 16 mm" },
                "mic": { "s_breakpoint": "≤ 16 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 32 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Ciprofloxacin",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "5 µg", "s_breakpoint": "≥ 26 mm", "i_breakpoint": "22–25 mm", "r_breakpoint": "≤ 21 mm" },
                "mic": { "s_breakpoint": "≤ 0.25 µg/mL", "i_breakpoint": "0.5 µg/mL", "r_breakpoint": "≥ 1 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Levofloxacin",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "5 µg", "s_breakpoint": "≥ 21 mm", "i_breakpoint": "17–20 mm", "r_breakpoint": "≤ 16 mm" },
                "mic": { "s_breakpoint": "≤ 0.5 µg/mL", "i_breakpoint": "1 µg/mL", "r_breakpoint": "≥ 2 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Trimethoprim-sulfamethoxazole",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "1.25/23.75 µg", "s_breakpoint": "≥ 16 mm", "i_breakpoint": "11–15 mm", "r_breakpoint": "≤ 10 mm" },
                "mic": { "s_breakpoint": "≤ 2/38 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 4/76 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Cefotaxime",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "30 µg", "s_breakpoint": "≥ 26 mm", "i_breakpoint": "23–25 mm", "r_breakpoint": "≤ 22 mm" },
                "mic": { "s_breakpoint": "≤ 1 µg/mL", "i_breakpoint": "2 µg/mL", "r_breakpoint": "≥ 4 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Ceftriaxone",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "30 µg", "s_breakpoint": "≥ 26 mm", "i_breakpoint": "20–22 mm", "r_breakpoint": "≤ 19 mm" },
                "mic": { "s_breakpoint": "≤ 1 µg/mL", "i_breakpoint": "2 µg/mL", "r_breakpoint": "≥ 4 µg/mL" },
                "comments": []
              }
            ]
          }
        ]
      },
      {
        "tier": 2,
        "tierDescription": "Appropriate for routine, primary testing, may be reported following cascade reporting rules.",
        "agents": [
          {
            "agentName": "Cefuroxime (Parenteral)",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "30 µg", "s_breakpoint": "≥ 23 mm", "i_breakpoint": "18–22 mm", "r_breakpoint": "≤ 17 mm" },
                "mic": { "s_breakpoint": "≤ 4 µg/mL", "i_breakpoint": "8–16 µg/mL", "r_breakpoint": "≥ 32 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Cefepime",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "30 µg", "s_breakpoint": "≥ 25 mm", "i_breakpoint": "19–24 mm", "r_breakpoint": "≤ 18 mm" },
                "mic": { "s_breakpoint": "≤ 4 µg/mL", "i_breakpoint": "8 µg/mL", "r_breakpoint": "≥ 16 µg/mL" },
                "comments": [ "Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production." ]
              }
            ]
          },
          {
            "agentName": "Ertapenem",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "10 µg", "s_breakpoint": "≥ 22 mm", "i_breakpoint": "19–21 mm", "r_breakpoint": "≤ 18 mm" },
                "mic": { "s_breakpoint": "≤ 0.5 µg/mL", "i_breakpoint": "1 µg/mL", "r_breakpoint": "≥ 2 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Imipenem",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "10 µg", "s_breakpoint": "≥ 23 mm", "i_breakpoint": "20–22 mm", "r_breakpoint": "≤ 19 mm" },
                "mic": { "s_breakpoint": "≤ 1 µg/mL", "i_breakpoint": "2 µg/mL", "r_breakpoint": "≥ 4 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Meropenem",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "10 µg", "s_breakpoint": "≥ 23 mm", "i_breakpoint": "20–22 mm", "r_breakpoint": "≤ 19 mm" },
                "mic": { "s_breakpoint": "≤ 1 µg/mL", "i_breakpoint": "2 µg/mL", "r_breakpoint": "≥ 4 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Cefotetan",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "30 µg", "s_breakpoint": "≥ 21 mm", "i_breakpoint": "13–15 mm", "r_breakpoint": "≤ 12 mm" },
                "mic": { "s_breakpoint": "≤ 16 µg/mL", "i_breakpoint": "32 µg/mL", "r_breakpoint": "≥ 64 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Cefoxitin",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "30 µg", "s_breakpoint": "≥ 18 mm", "i_breakpoint": "15–17 mm", "r_breakpoint": "≤ 14 mm" },
                "mic": { "s_breakpoint": "≤ 16 µg/mL", "i_breakpoint": "32 µg/mL", "r_breakpoint": "≥ 64 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Tetracycline",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "30 µg", "s_breakpoint": "≥ 15 mm", "i_breakpoint": "12–14 mm", "r_breakpoint": "≤ 11 mm" },
                "mic": { "s_breakpoint": "≤ 4 µg/mL", "i_breakpoint": "8 µg/mL", "r_breakpoint": "≥ 16 µg/mL" },
                "comments": [ "Organisms susceptible to tetracycline are also considered susceptible to doxycycline and minocycline." ]
              }
            ]
          }
        ]
      },
      {
        "tier": 3,
        "tierDescription": "Appropriate for high-risk Multi-Drug Resistant Organism (MDRO) patients, subject to cascade reporting.",
        "agents": [
          {
            "agentName": "Cefiderocol",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "30 µg", "s_breakpoint": "≥ 16 mm", "i_breakpoint": "9–15 mm", "r_breakpoint": "≤ 8 mm" },
                "mic": { "s_breakpoint": "≤ 4 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 8 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Ceftazidime-avibactam",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "30/20 µg", "s_breakpoint": "≥ 21 mm", "i_breakpoint": null, "r_breakpoint": "≤ 20 mm" },
                "mic": { "s_breakpoint": "≤ 8/4 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 16/4 µg/mL" },
                "comments": [ "Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm." ]
              }
            ]
          },
          {
            "agentName": "Imipenem-relebactam",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "10/25 µg", "s_breakpoint": "≥ 25 mm", "i_breakpoint": "21–24 mm", "r_breakpoint": "≤ 20 mm" },
                "mic": { "s_breakpoint": "≤ 1/4 µg/mL", "i_breakpoint": "2/4 µg/mL", "r_breakpoint": "≥ 4/4 µg/mL" },
                "comments": [ "Important Comment for Proteus sp.: These breakpoints do not apply to the family Morganellaceae, which includes but is not limited to the genera Morganella, Proteus, and Providencia." ]
              }
            ]
          },
          {
            "agentName": "Meropenem-vaborbactam",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "20/10 µg", "s_breakpoint": "≥ 18 mm", "i_breakpoint": "15–17 mm", "r_breakpoint": "≤ 14 mm" },
                "mic": { "s_breakpoint": "≤ 4/8 µg/mL", "i_breakpoint": "8/8 µg/mL", "r_breakpoint": "≥ 16/8 µg/mL" },
                "comments": [ "If an OXA-48-like gene or enzyme is detected, suppress or report as resistant." ]
              }
            ]
          },
          {
            "agentName": "Plazomicin",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "30 µg", "s_breakpoint": "≥ 18 mm", "i_breakpoint": "15–17 mm", "r_breakpoint": "≤ 14 mm" },
                "mic": { "s_breakpoint": "≤ 2 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 4 µg/mL" },
                "comments": []
              }
            ]
          }
        ]
      },
      {
        "tier": 4,
        "tierDescription": "May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.",
        "agents": [
          {
            "agentName": "Aztreonam",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "30 µg", "s_breakpoint": "≥ 21 mm", "i_breakpoint": "18–20 mm", "r_breakpoint": "≤ 17 mm" },
                "mic": { "s_breakpoint": "≤ 4 µg/mL", "i_breakpoint": "8 µg/mL", "r_breakpoint": "≥ 16 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Ceftazidime",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "30 µg", "s_breakpoint": "≥ 21 mm", "i_breakpoint": "18–20 mm", "r_breakpoint": "≤ 17 mm" },
                "mic": { "s_breakpoint": "≤ 8 µg/mL", "i_breakpoint": "16 µg/mL", "r_breakpoint": "≥ 32 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Ceftolozane-tazobactam",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": "30/10 µg", "s_breakpoint": "≥ 22 mm", "i_breakpoint": "19–21 mm", "r_breakpoint": "≤ 18 mm" },
                "mic": { "s_breakpoint": "≤ 2/4 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 4/4 µg/mL" },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Colistin or Polymyxin B",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": { "diskContent": null, "s_breakpoint": null, "i_breakpoint": null, "r_breakpoint": null },
                "mic": { "s_breakpoint": "≤ 2 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 4 µg/mL" },
                "comments": [ "Disk diffusion and gradient diffusion methods should not be performed for these agents. Note: Proteus is intrinsically resistant." ]
              }
            ]
          }
        ]
      },
      {
        "tier": 5,
        "tierDescription": "Urine Only Tier: Designated for reporting only on organisms isolated from the urinary tract.",
        "agents": [
          {
            "agentName": "Cefazolin",
            "breakpointSets": [
              {
                "condition": "Uncomplicated UTI only",
                "diskDiffusion": { "diskContent": "30 µg", "s_breakpoint": "≥ 15 mm", "i_breakpoint": null, "r_breakpoint": "≤ 14 mm" },
                "mic": { "s_breakpoint": "≤ 16 µg/mL", "i_breakpoint": null, "r_breakpoint": "≥ 32 µg/mL" },
                "comments": [ "Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis." ]
              }
            ]
          },
          {
            "agentName": "Nitrofurantoin",
            "breakpointSets": [
              {
                "condition": "Urine Only",
                "diskDiffusion": { "diskContent": "300 µg", "s_breakpoint": "≥ 17 mm", "i_breakpoint": "15–16 mm", "r_breakpoint": "≤ 14 mm" },
                "mic": { "s_breakpoint": "≤ 32 µg/mL", "i_breakpoint": "64 µg/mL", "r_breakpoint": "≥ 128 µg/mL" },
                "comments": [ "Note: Proteus is intrinsically resistant." ]
              }
            ]
          },
          {
            "agentName": "Fosfomycin",
            "breakpointSets": [
              {
                "condition": "Urine Only",
                "diskDiffusion": { "diskContent": "200 µg", "s_breakpoint": "≥ 16 mm", "i_breakpoint": "13–15 mm", "r_breakpoint": "≤ 12 mm" },
                "mic": { "s_breakpoint": "≤ 64 µg/mL", "i_breakpoint": "128 µg/mL", "r_breakpoint": "≥ 256 µg/mL" },
                "comments": [ "Important Note: Disk diffusion and MIC breakpoints for Fosfomycin apply only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species, which includes Proteus sp." ]
              }
            ]
          }
        ]
      }
    ]
  },
  "additionalInformation": {
    "diagnosticNotes": {
      "summary": "Diagnostic imaging is recommended for upper tract or recurrent infections to assess for stones or obstructive uropathy.",
      "biosafetyWarning": "",
      "methods": []
    },
    "preventionAndScreening": [],
    "treatmentLifecycle": [],
    "antimicrobialStewardship": [
      "Reserve carbapenems for mixed infections or for documented ESBL-producing strains.",
      "Reserve ceftazidime-avibactam and meropenem-vaborbactam for documented carbapenemase producers.",
      "Check susceptibility of all carbapenems if use is considered."
    ],
    "drugSpecificPearls": [
      {
        "drugName": "Piperacillin-tazobactam",
        "pearl": "Do not use for suspected or proven ESBL production due to reported clinical failures."
      },
      {
        "drugName": "Ceftazidime-avibactam + Aztreonam",
        "pearl": "The rationale for this combination is to use aztreonam (which is not hydrolyzed by MBLs) and protect it with avibactam from other co-produced beta-lactamases (e.g., ESBLs, AmpC, KPCs)."
      },
      {
        "drugName": "Cefiderocol",
        "pearl": "FDA-approved for complicated UTI with limited alternatives. A trial showed no statistically significant difference in mortality vs best available therapy (BAT)."
      },
      {
        "drugName": "Aztreonam-avibactam",
        "pearl": "This combination is in late stages of development and may be a future option."
      }
    ],
    "guidelineReferences": [
      {
        "source": "IDSA",
        "citation": "IDSA Guideline on treatment of ESBL, AmpC, and carbapenemase producers: Updated 2024 IDSA Guidelines.",
        "summaryOrNote": "Referenced for treatment strategies against resistant phenotypes."
      }
    ]
  }
}
